LUMO News and Press, Lumos Pharma Inc. From 05/19/21

AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on J...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 20...

Lumos Pharma, Inc. (LUMO) Q1 2021 Earnings Conference Call May 05, 2021 16:30 ET Company Participants Lisa Miller - Director-Investor Relations Rick Hawkins - President, Chairman & Chief Executive Officer John McKew - Chief Operating Officer & Chief Scientific Officer Gene Kennedy - C...

Lumos Pharma (LUMO): Q1 GAAP EPS of -$1.04 misses by $0.17.Cash and cash equivalents of $114.1MPress Release For further details see: Lumos Pharma EPS misses by $0.17

Newly released PK/PD data from prior study in PGHD support endogenous LUM-201 MOA and use of Predictive Enrichment Markers (PEMs) to identify patients likely to respond to LUM-201 Data presented at ENDO 2021 differentiate LUM-201 from standard GH secretagogues and show its p...

AUSTIN, Texas, April 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its first quarter 2021 financial results after market close on Wednesday, May 5, 2021....

AUSTIN, Texas, April 27, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that new data highlights from three patients with pediatric growth hormone deficiency (PGHD) previous...

Lumos Pharma (LUMO) CFO Carl Langren has announced his plans to retire effective as of July 4, 2021; Mr. Langren has served as CFO of the Company since November 2018.He will continue to serve as consultant for a transitory period to ensure a smooth succession process.Lori Lawle...

AUSTIN, Texas, April 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes to its executive team as the Company celebrates one year since the close of its merger. ...